| Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids YJ Li, JF Fahrmann, M Aftabizadeh, Q Zhao, SC Tripathi, C Zhang, ... Cell reports 39 (9), 2022 | 55 | 2022 |
| CD44 in ovarian cancer progression and therapy resistance—a critical role for STAT3 A Martincuks, PC Li, Q Zhao, C Zhang, YJ Li, H Yu, ... Frontiers in oncology 10, 589601, 2020 | 53 | 2020 |
| PARP inhibition activates STAT3 in both tumor and immune cells underlying therapy resistance and immunosuppression in ovarian cancer A Martincuks, J Song, A Kohut, C Zhang, YJ Li, Q Zhao, E Mak, ... Frontiers in Oncology 11, 724104, 2021 | 20 | 2021 |
| Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis M Aftabizadeh, YJ Li, Q Zhao, C Zhang, N Ambaye, J Song, T Nagao, ... JCI insight 6 (2), 2021 | 16 | 2021 |
| Niraparib-induced STAT3 inhibition increases its antitumor effects Q Zhao, A Kohut, YJ Li, A Martincuks, T Austria, C Zhang, NL Santiago, ... Frontiers in Oncology 12, 966492, 2022 | 4 | 2022 |
| STAT3 is a potential therapeutic target in cervical cancer (257) A Kohut, A Martincuks, NL Santiago, T Austria, Q Zhao, S Lee, A Tergas, ... Gynecologic Oncology 166, S137-S138, 2022 | 1 | 2022 |
| A Platform to Deliver Single and Bi-specific Cas9/guide RNA to Perturb Genes in Vitro and in Vivo YJ Li, SH Chien, R Huang, A Herrmann, Q Zhao, PC Li, C Zhang, ... Molecular Therapy, 2024 | | 2024 |
| Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer A Martincuks, C Zhang, T Austria, YJ Li, R Huang, NL Santiago, A Kohut, ... Journal for Immunotherapy of Cancer 12 (4), 2024 | | 2024 |
| Combination of Ibrutinib with CD19 Chimeric Antigen Receptor (CAR) T Cells Suggests Greater Contribution to CAR T-Cell Efficacy Than Other Approved BTK Inhibitors in the … V Plaks, V Cyril, PA Riedell, Q Zhao, J Hall, J Tan, D Harb, MS Davids Blood 142, 2817, 2023 | | 2023 |
| EP245/# 993 Niraparib induces ovarian cancer cell apoptosis regardless of homologous recombination status through downregulation of the oncogenic SRC/STAT3 axis A Kohut, Q Zhao, YJ Li, A Martincuks, T Austria, C Zhang, N Lugo, ... International Journal of Gynecologic Cancer 32 (Suppl 3), 2022 | | 2022 |
